KCI Corporate Profile — KCI Page 1 of 2

KCI Corporate Profile

Overview
Kinetic Concepts, Inc. (NYSE: KCI) is a leading global medical technology company devoted to the
discovery, development, manufacture and marketing of innovative, high-technology therapies and
products for the wound care, regenerative medicine and therapeutic support system markets. KCI’s
product portfolio offers healthcare professionals and their patients a proven clinical advantage in all care
settings with therapies that improve patient outcomes while helping to reduce the overall cost of care. For
more information, visit the company’s Web site at www.kci1.com.

A History of Innovation
KCI was founded in 1976 by Dr. Jim Leininger who, as an emergency room physician, pioneered the use
of “kinetic” or motion therapy to dramatically improve the survival rates for patients who are immobile due
to critical injury. Today, KCI develops therapeutic support systems that address a full range of specialized
patient needs including products for the wound care, bariatric and critical care markets. In 1996, KCI
introduced an innovative approach to the treatment and management of serious, complex wounds
through the use of sub-atmospheric or negative pressure. Known today as “negative pressure wound
therapy” (NPWT) KCI’s proprietary Vacuum Assisted Closure®, or V.A.C.® Therapy System has changed
the advanced wound care market and remains the most clinically proven alternative for the treatment and
management of complex, hard-to-heal wounds, ulcers, and partial thickness burns.

Research and Development (R&D)

KCI continues to invest in innovation with an ongoing commitment to research and development aimed at
improving patient outcomes while reducing the overall cost of care. In 2008, KCI invested approximately
$76 million in its R&D efforts, which are managed by approximately 240 clinical research and
development professionals.

Clinical Studies
KCI's product portfolio has an unprecedented body of clinical evidence that demonstrates clinical efficacy
and cost-effectiveness. KCI's V.A.C Therapy System is the leader, with:

 22 Randomized Clinical Trials

 More than 615 Peer Reviewed Articles

 More than 815 Abstracts

 71 Medical Text Book Citations

Therapies
KCI’s products address a full range of patient needs and are used by healthcare professionals around the
world in a wide range of care settings, including acute care hospitals, long-term care and skilled nursing
facilities, home health agencies and wound care clinics throughout the world.

V.A.C. Therapy® — The KCI V.A.C. Therapy System is the only NPWT indicated for promoting wound
healing that include specific mechanisms of action such as preparing the wound bed for closure, reducing
edema, promoting granulation tissue formation and perfusion, and removing exudate and infectious
material. KCI’s ActiV.A.C. ® Therapy System, which is designed for ambulatory patients, remains the only
NPWT alternative that is specifically cleared for home use.

Regenerative Medicine — KCI entered the fast-growing tissue regeneration market in 2008 with the
acquisition of LifeCell Corporation, a leading provider of human and porcine- based tissue regeneration
products. LifeCell develops and markets products for use in reconstructive, orthopedic and
urogynecologic surgical procedures utilizing its AlloDerm® Regenerative Tissue Matrix and Strattice™
Reconstructive Tissue Matrix products.

Therapeutic Support Systems — KCI has a product portfolio that includes a full range of specialty
hospital beds, mattress replacement systems and overlays designed to address pulmonary complications
associated with immobility, reduce skin breakdown, and assist caregivers in the safe and dignified
handling of bariatric patients.

KCI at a Glance*
Worldwide Headquarters San Antonio, Texas

President and CEO Catherine M. Burzik

Web Address www.kci1.com

Stock Exchange NYSE: KCI

Primary Business Medical devices

Employees ~6,700

Operations In 20 countries

Manufacturing Locations U.S. and Ireland

http://www.kci1.com/cs/Satellite?c=Page&childpagename=KCI1%2FKCILayout&cid=12... 1/25/2011
KCI Corporate Profile — KCI Page 2 of 2

2009 Annual Revenue $1,993 million

2009 Net Earnings $228.7 million

2009 Net Earnings Per Diluted Share $3.24

2009 Research and Development Investment $92.0 million

Revenue by Region and Business ($mm)

U.S. International Total

Advanced Healing Solutions $1,066 $340 $1,407

Therapeutic Support Systems 196 104 300

Lifecell 284 2 286

Total $1,547 $446 $1,993

Financial
 Original NASDAQ IPO in 1988

 Leveraged buy-out in 1997

 Second IPO in February 2004 on NYSE, resulting in one of largest medical technology IPOs in U.S.
history

 KCI was added to Standard & Poor’s MidCap 400 Index in 2007

Global Presence
KCI does business in more than 20 countries in Europe, the Middle East and Africa (EMEA) and Asia
Pacific regions. KCI’s worldwide headquarters is located in San Antonio, Texas. KCI’s EMEA Region
office is located in Amsterdam, The Netherlands. KCI’s Asia Pacific Region has offices in Shanghai,
China and Singapore.

Contact:
Kinetic Concepts, Inc.
Joe Izbrand
Office: 210-255-6251; Wireless: 210-867-9934
Media@kci1.com

Updated: January 25, 2011

http://www.kci1.com/cs/Satellite?c=Page&childpagename=KCI1%2FKCILayout&cid=12... 1/25/2011